Cross-domain alignment between bulk and single-cell transcriptomes remains a major computational challenge because bulk and single-cell RNA sequencing data exhibit substantial domain discrepancies arising from sparsity, technical noise, and difference...
Cross-domain alignment between bulk and single-cell transcriptomes remains a major computational challenge because bulk and single-cell RNA sequencing data exhibit substantial domain discrepancies arising from sparsity, technical noise, and differences in transcriptional resolution. These discrepancies hinder the generalization of predictive models trained on bulk transcriptomic datasets when applied to single-cell data. Although recent transfer learning approaches have attempted to address this problem through latent feature alignment, many existing methods rely on gene-level representations that are sensitive to transcriptional noise and provide limited biological interpretability. To address these limitations, this study proposes a biologically informed few-shot label-guided domain adaptation framework for constructing a shared co-embedding space between bulk and single-cell transcriptomes. The proposed framework employs pathway-specific denoising autoencoders to encode transcriptomic profiles into pathway-level latent embeddings, enabling biologically guided dimensionality reduction while mitigating technical noise. To align transcriptomic modalities, the framework applies few-shot label-guided contrastive learning that selectively aligns bulk and single-cell samples sharing the same drug response states within the pathway embedding space. A limited number of labeled single-cell samples are utilized to guide cross-domain representation alignment, while the prediction module is trained using bulk drug response supervision and subsequently transferred to the single-cell domain. In addition, a multi-head attention module integrates pathway-level embeddings to capture pathway importance and interactions associated with heterogeneous cellular responses. Experimental evaluations across multiple benchmark datasets demonstrated that the proposed framework consistently outperformed existing baseline methods, including scDEAL, SCAD, and Celligner-based approaches, in weighted F1-score, AUPRC, and AUROC. Furthermore, pathway-level analyses identified biologically meaningful signaling signatures associated with drug-specific response patterns, demonstrating the interpretability and robustness of the proposed framework for single-cell drug response prediction.